Interventional Spine, Inc. announced FDA clearance of the 80 Lumbar Lordotic Opticage™ Expandable Intervertebral Body Fusion Device, indicated for use with autogenous bone graft in patients with degenerative disc disease at one or two contiguous levels from L2-S1.
This device joins the Interventional Spine family of Opticage™ Expandable Interbody Fusion implants cleared in 4Q15, and can also be used with the company’s PerX360 System™.
Opticage can be implanted via posterior, transforaminal or lateral approach.Source: Interventional Spine, Inc.
Interventional Spine, Inc. announced FDA clearance of the 80 Lumbar Lordotic Opticage™ Expandable Intervertebral Body Fusion Device, indicated for use with autogenous bone graft in patients with degenerative disc disease at one or two contiguous levels from L2-S1.
This device joins the Interventional Spine family of Opticage™ Expandable...
Interventional Spine, Inc. announced FDA clearance of the 80 Lumbar Lordotic Opticage™ Expandable Intervertebral Body Fusion Device, indicated for use with autogenous bone graft in patients with degenerative disc disease at one or two contiguous levels from L2-S1.
This device joins the Interventional Spine family of Opticage™ Expandable Interbody Fusion implants cleared in 4Q15, and can also be used with the company’s PerX360 System™.
Opticage can be implanted via posterior, transforaminal or lateral approach.Source: Interventional Spine, Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
